Supernus Pharmaceuticals Inc (SUPN)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

9715 KEY WEST AVENUE ROCKVILLE, MD 20850

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy; Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy; APOKYN® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson's disease (PD); MYOBLOC® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults; and XADAGO® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD; SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations ("on-off" episodes) in PD; SPN-820 for treatment-resistant depression; and SPN-817 for the treatment of epilepsy.

Data as of 2021-07-19 09:05:17 -0400
Market Cap1.402 Billion Shares Outstanding53.019 Million Avg 30-day Volume471.6 Thousand
P/E Ratio12.6194 Dividend Yield EPS2.06
Price/Sales2.52 Debt to Equity2.0 EBITDA182.529 Million
Price to Book Value1.86 Forward PE1.76 Enterprise Value1.396 Billion
Total Cash391.101 Million Current Debt240.812 Million Gross Profit493.092 Million
BETA1.16172 52-week High/Low34.29 / 17.2 Next Earnings Date2021-08-09 Price to Cash FLow (P/CF) 139.2655
Data provided by IEX Cloud
View SEC Filings from SUPN instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 3 3 0.0% 4 (0.23%) 4 (0.23%) 0.0%
Funds Holding: 217 223 -2.69% 54 (3.17%) 63 (3.66%) -14.29%
13F shares: 52.821 Million 52.92 Million -0.19% 17.099 Million 18.5 Million -7.57%
% Ownership 99.8064 32.3092 35.1134 -7.99%
New Positions: 33 39 -15.38% 7 11 -36.36%
Increased Positions 75 73 2.74% 19 22 -13.64%
Closed Positions 33 22 50.0% 14 12 16.67%
Reduced Positions 73 82 -10.98% 22 27 -18.52%
Total Calls 128.163 Thousand 173.265 Thousand -26.03% 30.7 Thousand 14.4 Thousand 113.19%
Total Puts 34.841 Thousand 52.609 Thousand -33.77% 20.1 Thousand 22.9 Thousand -12.23%
PUT/CALL Ratio 0.27 0.3 -10.0% 0.65 1.59 -59.12%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding SUPN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SUPN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MARTIN TAMI TILLOTSON SR. V.P., REGULATORY AFFAIRS

  • Officer
188,277 2021-04-13 2

KHATTAR JACK A. PRESIDENT, CEO

  • Officer
  • Director
1,578,916 2021-03-26 3

BHATT PADMANABH P. SR. VP OF IP, CSO

  • Officer
17,000 2021-02-19 1

NEWHALL CHARLES W III

  • Director
109,096 2021-02-19 1

HUDSON FREDERICK M.

  • Director
29,628 2021-02-19 1

SIEBERT JOHN M

  • Director
72,540 2021-02-19 1

GEMAYEL GEORGES

  • Director
16,798 2021-02-19 1

BARLOW CARROLEE

  • Director
16,798 2021-02-19 1

MOTTOLA FRANK SVP, QUALITY, GMP OPS. & IT

  • Officer
23,839 2021-02-19 1

KELLY JAMES PATRICK EXECUTIVE VICE-PRESIDENT & CFO

  • Officer
15,000 2021-02-19 3

RUBIN JONATHAN SVP, CHIEF MEDICAL OFFICER

  • Officer
25,000 2021-02-19 2

SCHWABE STEFAN K.F. EXECUTIVE VICE PRESIDENT & CMO

  • Officer
2,772 2020-12-21 2

PATRICK GREGORY S SR. VP CHIEF FINANCIAL OFFICER

  • Officer
44,463 2020-11-09 4

LENGAUER CHRISTOPH

  • Director
0 2019-04-17 0

MATUSHANSKY IGOR CHIEF MEDICAL OFFICER

  • Officer
0 2019-04-17 0

PINSCHEWER DAVID CHIEF SCIENTIFIC OFFICER

  • Officer
0 2019-04-17 0

VAUGHN VICTOR SR. VP OF SALES & MARKETING

  • Officer
9,344 2018-04-18 0

NUERGE WILLIAM A.

  • Director
23,750 2017-06-13 0

BARRETT M JAMES

  • Director
212,710 2016-03-16 0

NEW ENTERPRISE ASSOCIATES 11 LP

  • 10% Owner
No longer subject to file 2015-11-11 0

NEA PARTNERS 11 LP

  • 10% Owner
No longer subject to file 2015-11-11 0

SANDELL SCOTT D

  • 10% Owner
No longer subject to file 2015-11-11 0

KOLLURI KRISHNA KITTU

  • 10% Owner
No longer subject to file 2015-11-11 0

BASKETT FOREST

  • 10% Owner
No longer subject to file 2015-11-11 0

BARRIS PETER J

  • 10% Owner
No longer subject to file 2015-11-11 0

BRYAN JONES W. VP OF BUSINESS DEVELOPMENT

  • Officer
67,980 2015-03-30 0

BIGHAM MICHAEL

  • Director
25,000 2013-03-20 0

ORBIMED ADVISORS LLC

ISALY SAMUEL D

ORBIMED CAPITAL GP II LLC

  • 10% Owner
No longer subject to file 2013-02-12 0

NEW ENTERPRISE ASSOCIATES 11 LP

NEA PARTNERS 11 LP

NEA 11 GP, LLC

BARRIS PETER J

BASKETT FOREST

DRANT RYAN D

KOLLURI KRISHNA KITTU

KRAMLICH C RICHARD

PERRY MARK W

SANDELL SCOTT D

  • 10% Owner
10,641,250 2012-05-04 0

SHEFFERY MICHAEL B

  • Director
6,099,996 2012-05-04 0

ABINGWORTH MANAGEMENT LTD

  • 10% Owner
3,600,000 2012-05-04 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 22:15:03 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 21:45:03 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 21:15:03 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 20:45:03 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 20:15:05 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 19:45:03 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 19:15:03 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 18:45:03 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 18:15:03 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 17:45:03 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 17:15:02 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 16:45:02 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 16:15:03 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 15:45:02 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 15:15:03 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 14:45:03 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 14:15:03 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 13:45:03 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 13:15:03 UTC -0.17 0.25 3600000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-07-23 12:45:03 UTC -0.17 0.25 3600000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Calamos Investment Trust/IL- Calamos Market Neutral Income Fund SUPN -36000.0 shares, $-1096200.0 2021-04-30 N-PORT

Elevate your investments